NBP 606

Drug Profile

NBP 606

Alternative Names: 13-valent pneumococcal vaccine conjugate - SK Chemicals; 13vPnC - SK Chemicals; NBP-606

Latest Information Update: 12 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SK Chemicals
  • Class Pneumococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Pneumococcal infections

Most Recent Events

  • 21 Apr 2016 NBP 606 is still in phase III trials for Pneumococcal infections (Prevention) in South Korea
  • 01 Mar 2015 SK Chemials completes a phase III trial in Pneumococcal infections (prevention, in elderly, treatment-naive) in South Korea (IM) (NCT02079207)
  • 01 Jul 2014 SK Chemicals plans a phase III trial in Pneumococcal infections (prevention, in infants) in South Korea (NCT02201030)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top